drugset
drugset / Trial / NCT00079183

Sirolimus as Secondary Therapy in Chronic Graft-Versus-Host Disease Not Responding To Prior Treatment

NCT00079183 ↗

Phase 2 Completed 44 enrolled Fred Hutchinson Cancer Center National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelSupportive care

Summary

This phase II trial studies the side effects and how well sirolimus works as secondary therapy in treating patients with chronic graft-versus-host disease (GVHD) that did not respond to prior treatment. Sirolimus may be an effective treatment for chronic GVHD

Timeline

Start
2002-04
Primary completion
2009-07
Completion
2010-06-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Sirolimus Small molecule — Oral

Indications

chronic graft versus host disease